Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 1:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 60 matching trials from the live ClinicalTrials.gov search.
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction, Cardiovascular Diseases, Heart Diseases
Interventions
Tovinontrine (CRD-750), Placebo
Drug
Lead sponsor
Cardurion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
26
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 23 more
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
Point of Care Ultrasound
Device
Lead sponsor
Corewell Health West
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Grand Rapids, Michigan
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions
Vericiguat, Placebo
Drug
Lead sponsor
Josef Stehlik
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Salt Lake City, Utah
Conditions
Heart Failure NYHA Class III
Interventions
BaroStim
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Riverhead, New York
Conditions
Heart Failure
Interventions
AZD3427, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
10
States / cities
Little Rock, Arkansas • Glendale, California • Daytona Beach, Florida + 7 more
Conditions
Acute Heart Failure
Interventions
sacubitril/valsartan (LCZ696), Enalapril, sacubitril/valsartan (LCZ696) matching placebo, enalapril matching placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
887 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
123
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Little Rock, Arkansas + 105 more
Recruiting Phase 2 Interventional

A Trial of CRD-4730 in HFrEF

NCT07750873
Conditions
Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions
CRD-4730, Placebo
Drug
Lead sponsor
Cardurion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Pasadena, California • Bloomfield Hills, Michigan
Conditions
Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement, Conduction Defect, Heart Failure, Valvular Heart Disease, Ischemic Heart Disease, Cardiotoxicity, Myocardial Infarction, Dilated Cardiomyopathy, HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Syncope, Remodeling, Cardiac
Interventions
15-minutes of sitting during COR ECG Acquistion
Device
Lead sponsor
Peerbridge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
8
States / cities
Orange, California • Pasadena, California • Detroit, Michigan + 5 more
Conditions
Heart Failure
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
41
States / cities
Mobile, Alabama • Saraland, Alabama • Huntington Beach, California + 37 more
Conditions
Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions
Dapagliflozin, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 150 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
23
States / cities
Alexander City, Alabama • Fairhope, Alabama • Fort Payne, Alabama + 19 more
Conditions
Heart Failure With Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
Interventions
AccuCinch Ventricular Restoration System, Guideline-Directed Medical Therapy
Device · Drug
Lead sponsor
Ancora Heart, Inc.
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
96
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 75 more
Recruiting Not applicable Interventional

Alleviant ALLAY-HFrEF Study

NCT06812533
Conditions
Heart Failure
Interventions
Alleviant ALV1 System, Sham-Control
Device · Other
Lead sponsor
Alleviant Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
40
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 31 more
Conditions
Heart Failure
Interventions
Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
18
States / cities
Fountain Valley, California • Wilmington, Delaware • Fort Lauderdale, Florida + 15 more
Conditions
Congestive Heart Failure, Heart Failure, Systolic, Heart Failure, HFrEF - Heart Failure With Reduced Ejection Fraction
Interventions
SRD-001, Placebo
Biological · Drug
Lead sponsor
Sardocor Corp.
Industry
Eligibility
18 Years to 80 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
5
States / cities
San Diego, California • San Francisco, California • St Louis, Missouri + 2 more
Conditions
Heart Failure With Reduced Ejection Fraction, Congestion
Interventions
Ertugliflozin, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
New York, New York
Conditions
Heart Failure With Reduced Ejection Fraction (HFrEF), or Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
Interventions
XXB750, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Inverness, Florida • Jacksonville, Florida • Saint Paul, Minnesota
Terminated Phase 2 Interventional Results available

Effectiveness of CRD-740 in Heart Failure

NCT05409183
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Cardiovascular Diseases, Heart Diseases
Interventions
CRD-740, Placebo
Drug
Lead sponsor
Cardurion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
17
States / cities
Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 13 more
Recruiting Early Phase 1 Interventional

Ketones, SGLT2, HFrEF

NCT06229678
Conditions
Type2diabetes, Heart Failure With Reduced Ejection Fraction
Interventions
Empagliflozin 25 MG Oral Tablet, Placebo, Acipimox 250 Mg Oral Capsule
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Completed Phase 1Phase 2 Interventional Results available

Developing Oral LT3 Therapy for Heart Failure - HFrEF

NCT04112316
Conditions
Heart Failure With Reduced Ejection Fraction (HFrEF), Low T3 Syndrome
Interventions
Liothyronine, Placebo
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Hyperkalaemia, Heart Failure With Reduced Ejection Fraction
Interventions
Sodium zirconium cyclosilicate, Placebo, Spironolactone
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Fairhope, Alabama • Los Angeles, California • Torrance, California + 9 more
Conditions
Heart Failure With Reduced Ejection Fraction, Endothelial Dysfunction
Interventions
TVS, Sham TVS
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
Chronic Heart Failure
Interventions
JTT-861 Capsules, Placebo Capsules
Drug
Lead sponsor
Shionogi Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
20
States / cities
Phoenix, Arizona • Crystal River, Florida • Hialeah, Florida + 16 more
Conditions
Chronic Heart Failure With Reduced Ejection Fraction
Interventions
Vericiguat (BAY1021189) 5 mg
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
5
States / cities
Alexander City, Alabama • Richmond, Indiana • Baltimore, Maryland + 2 more
Conditions
Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions
AC01, Placebo
Drug · Other
Lead sponsor
AnaCardio AB
Industry
Eligibility
18 Years to 85 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Van Nuys, California • Crystal River, Florida • Schaumburg, Illinois + 1 more